Meanwhile, we also found that the expression of DPY30 in patients with moderately and highly differentiated pancreatic cancer was significantly lower than that in patients with poorly differentiated pancreatic cancer (Fig. 6c, d), further confirming that DPY30 accelerated the progression of pancreatic cancer. Here, DPY30 is linked to familial pancreatic carcinoma.